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Abstract
Background
Increasing patient-reported outcome measures in the 1980s and 1990s led to the develop-
ment of recommendations at the turn of the millennium for standardising outcome mea-
sures in non-specific low back pain (LBP) trials. Whether these recommendations impacted
use is unclear. Previous work has examined citation counts, but actual use and change
over time, has not been explored. Since 2011, there has been some consensus on the opti-
mal methods for reporting back pain trial outcomes. We explored reporting practice, out-
come measure use, and publications over time.
Methods
We performed a systematic review of LBP trials, searching the European Guidelines for the
management of LBP, extending the search to 2012. We abstracted data on publications by
year, outcome measure use, analytical approach, and approaches taken to reporting trials
outcomes. Data were analysed using descriptive statistics and regression analyses.
Results
We included 401 trials. The number of published trials per year has increased by a factor of
4.5 from 5.4 (1980–1999) to 24.4 (2000–2012). The most commonly used outcome mea-
sures have been the Visual Analogue Scale for pain intensity, which has slowly increased
in use since 1980/81 from 20% to 60% of trials by 2012, and the Roland-Morris Disability
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Questionnaire, which rose to 55% in 2002/2003, and then fell back to 28% by 2012. Most
trialists (85%) report between-group mean differences. Few (8%) report individual improve-
ments, and some (4%) report only within-group analyses. Student’s t test, ANOVA, and
ANCOVA regression, or mixed models, were the most common approaches to analysis.
Conclusions
Recommendations for standardising outcomes may have had a limited or inconsistent
effect on practice. Since the research community is again considering outcome measures
and modifying recommendations, groups offering recommendations should be cognisant
that better ways of generating trialist buy-in may be required in order for their recommenda-
tions to have impact.
Introduction
Patient-reported outcome measures (PROMs) are outcomes that are reported by patients,
rather than being objectively assessed or involving third-party (e.g. clinician) judgement.
Throughout the 1980s and 1990s, multiple back-specificPROMs were developed and began to
dominate as outcome measures used in non-specific low back pain (nsLBP) trials. Between
1998 and 2000 recommendations were made to standardise outcome measure use to facilitate
cross-trial comparisons, pooling of data, and encourage scale familiarity. [1–3] More recently,
researchers and clinicians have again begun to question whether the right things are beingmea-
sured and there have been calls to review the outcome measures used in trials. [4–8] It is not
clear whether the millennial recommendations for standardisation had an effect on practice.
Previous studies have explored the number of times back-specificmeasures have been cited,
but not actual use; also, trends of use over time have not hitherto been explored. [9, 10]
Results from trials using PROMs can be reported differently, and this is known to affect cli-
nicians’ interpretations of effectiveness and subsequent decision-making. [11, 12] With this in
mind, recommendations for reporting outcomes in back pain trials were made in 2011 and
2014. [13, 14]
We aimed to explore actual use of outcome measures in nsLBP trials, between 1980 and
2012, spanning the publication point of the millennial core-set recommendations. Our objec-
tives were to identify the most commonly used outcomes, and the domain coverage of back-
specific PROMs, and to consider whether there was any change in the trajectories of outcome
measure use over the period of interest. Additionally, we reviewed the number of publications
over time, reportingmethods and analytical approaches for the most commonly used outcome
measures to provide a baseline assessment of current practice so that any future change may be
monitored.
Materials and Methods
Two independent reviewers (RF and SP) identified randomised controlled trials (RCTs) of any
intervention for nsLBP published in or after 1980, from COST-B13’s European Guidelines for
the Management of Low Back Pain (EGLBP), which included a comprehensive systematic
search of all interventions for nsLBP, and the systematic reviews reported in the EGLBP. [15]
As the COST-B13 search ended in November 2002, we extended the search to January 1, 2007
using the Cochrane Library, EMBASE, Lilacs, PsycINFO, and PubMed databases, and we
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hand-searched the Health Technology Assessment (HTA) journal.We later updated the search
to January 1, 2012, using the Cochrane Library, PubMed, and EMBASE database. We omitted
PsycINFO, Lilacs, and the HTA journal in this extension due to good cross-coverage from the
other databases (see Discussion). An example search strategy is included as a supplementary
file (S1 Text). We combined material from the EGLBP and the extended searches, removed
duplicates, and short-listed by title and abstract. Full-texts were obtained if the titles and
abstract alone contained insufficient information for assessment against the criteria listed in
Table 1.
Data abstraction and validation
Two reviewers (either RF, SP, TB, PB, or DR) independently abstracted data on outcome mea-
sure use, details of primary outcome analysis, and reportingmethods. An outcome was identi-
fied as ‘primary’ if (1) the outcome was nominated as such; if no outcome was nominated, or
multiple outcomes were nominated, we used (2) the outcome measure on which the sample
size calculation was based; if this was not reported, we identified (3) the first outcome measure
referred to in the abstract; and if this was not identified, we used (4) the first outcome men-
tioned in the paper. We identified the primary time point of interest, or used the first follow-up
time point in cases when this was not clear. This approach has been taken in other methodo-
logical reviews. [16–20] For comparison, a sensitivity analysis of primary outcome measure use
for the most commonly used outcome measures was performed using only criterion 1 and 2.
Disagreements were resolved through discussion and, if necessary, with arbitration and a third
reviewer (RF, SE, or MU).
Using Microsoft Visual Basic 6.3 (Microsoft,Washington) and Microsoft Office Excel 2003
(Microsoft,Washington), we developed a front-end program to assist the data abstraction pro-
cess and manage abstracted data, which validated entries and provided alerts in the case of
missed fields.
For outcome measure identification, we used expert validation of 20% of papers, as has been
done in other methodological reviews. [21] Half (i.e. 10%) were selected at random and half
(i.e. 10%) were purposively sampled (papers that we anticipated might lead to disagreement)
from the papers marked for full-text extraction and then given to an independent reviewer
(either SE, RF, SP, TB, PB, or DR), for independent abstraction. Since early in the process we
Table 1. Inclusion and exclusion criteria.
Order Inclusion criterion
1 RCTs of nsLBP
Exclusion criteria
1 Non-English language reports
2 Studies that were not RCTs or presented insufficient information for us to determine whether
randomisation was used to allocate participants
3 Reports that self-identified as pilot/feasibility studies
4 Cross-over designs (because of limited utility in the LBP field)
5 RCTs with mixed samples (e.g. neck or thoracic pain in addition to LBP), samples of participants
with radiating leg pain, or referred pain extending past the knee, or samples including LBP specific
pathology (e.g cancer, ankylosing spondylitis, or disc herniation) or pregnancy
6 Non-inferiority trials (because of limited utility in the LBP field)
7 Follow-up studies with no new outcome measures, and multiple publications. In the case of multiple
publications, we included the first published article and excluded subsequent publications
RCT = Randomised controlled trial; nsLBP = non-specific low back pain; LBP = low back pain.
doi:10.1371/journal.pone.0164573.t001
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observedgood (> 80%) agreement on outcome measurement identification, but inadequate
agreement on analytical and reportingmethods, full independent abstraction was subsequently
used to identify analytical approach and reportingmethods used. Disagreements were settled
by arbitration involving one of the statisticians (either RF or SE). Quality of included trials was
not evaluated, since we were interested in all non-specific back pain trials, regardless of the tri-
als’ methodological quality.
Analysis
To report the proportion of outcome measure use by year, the total number of trials is needed
as the denominator. For this reason, we first explored the number of published nsLBP trials by
year. Prevalence of outcome measure use and in the case of PROMs, domain of measurement,
was then calculated for primary and secondary outcomes, by year. We were particularly inter-
ested in PROM use, and we did not differentiate between different types of objective outcome
measure use, or clinical judgements.
Methods for reporting the two most commonly used outcome measures and the types of
analysis used were summarised using descriptive statistics and graphical methods. For report-
ing methods, we explored the statistics used to summarise central tendency and variance,
graphical forms of representation, and use of tables. For analytical approach, we explored the
statistical test used to test the null hypothesis that a between group difference was zero, or the
model that was fitted to the data. We used regression analysis to explore the relationship
between publications and time, and outcome measure use and time, fitting polynomial terms if
relationships were non-linear. Residuals from regression analysis were examined for fit. If data
were too heteroschedastic (i.e variance of an outcome variable was dependent on the value of a
predictor variable) for regression modelling, we fitted locally weighted scatter plot smoothing
(Lowess) lines, which has the effect of smoothing across erratic data points, so that trends can
bemore easily visualised. All analyses were performed in Stata, version 12 (Statacorp, Texas).
We did not publish a review protocol ahead of undertaking this work.
Results
We identified 7,066 potential articles from EGLBP and electronic databases and following
removal of duplicates, titles and abstracts sifting, and full-text inspection against inclusion cri-
teria, included 401 trials (Fig 1). Characteristics of included and excluded trials are detailed
with their references as supplementary material (S1 and S2 Tables).
Publications over time
A linear regression model with a quadratic term in year was significant (βyear = −166.187,
P = 0.002, βyear2 = 0.041, P = 0.002), and explained 79% of the variance (Fig 2). Some caution
must be noted with respect to interpretation, since as can be seen from Fig 2, these data are
slightly heteroschedastic. The number of publications increases after the millennium; the aver-
age number of publications per year from 1980 to 1999 is 5.4 and from 2000 to 2012 is 24.4.
Outcome measure use
Authors explicitly declared a primary outcome measure in 50% (n = 201) of trials. In trials that
did not declare one, a primary outcome measure could be identified from a sample size calcula-
tion in 20% (n = 40) of trials.We identified the primary as the first outcome measure men-
tioned in the abstract, or in the paper, in the remaining 40% (n = 161).
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The most commonly used PROMs were the Visual Analogue Scale for measuring Pain
intensity (VAS-P), [22], and the RolandMorris Disability Questionnaire (RMDQ), [23]
OswestryDisability Index (ODI), [24] Numerical Rating Scale for measuring pain intensity
(NRS), [25, 26] and patient-rated global assessment of improvement (i.e. a health transition
question (TQ) [27]) (Table 2 and Fig 3).
We note that we class the VAS-P and NRS as back-specific, since the wording of these
instruments, when used in back pain trials, typically refers specifically to a person’s back pain.
In total, there were 258 different PROMs used across the trials studied within the time period.
Sensitivity analyses of primary outcome measure use within only trials that either explicitly
declared the outcome measure as primary, or used it for a sample size calculation, revealed sim-
ilar estimates of primary outcome measure use in across outcome measures, with the possible
exception of the RMDQ (Table 2).
Apart from PROMs, objectively assessed outcome measures were also common (n = 130),
particularly as secondary outcome measures, as were medication and medical services con-
sumption (n = 66), and subjective clinical examinations (n = 19).
Fig 1. Flow chart showing search results. The figure shows the number of initial hits, duplicates, exclusions based on titles and abstracts
screening, and assessments at full text level evaluation.
doi:10.1371/journal.pone.0164573.g001
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Pain and disability were the most commonly measured domains (Fig 4). Some outcomes,
for example, adverse events, or adherence, have only ever beenmeasured as secondary out-
comes.We note that it is possible for the usage to exceed the number of included trials, which
is due to some trials using more than one outcome measure to measure within these domains.
The VAS-P has had a slowly increasing usage as an outcome measure in nsLBP trials,
increasing from from 20% in slowly increased in use since 1980/81 to 60% of trials by 2012.
There is some suggestion of a rise and fall in the use of the RMDQ, which peaks at 55% in
2002/2003. Use of the ODI has steadily increased. These data were too heteroschedastic for
regression analysis and we present the data graphically with a Lowess smoother (Fig 5). We
note the use of a large smoothing bandwidth to easily visualise trends; while the RMDQ
Fig 2. Number of published non-specific low back pain trials by publication year between 1980 and
2012. The figure shows the increase in the number of published non-specific low back pain trials by year of
publication and change in publication rate over time. A Lowess smoother is fitted to these data.
doi:10.1371/journal.pone.0164573.g002
Table 2. The most common back-specific PROMs: Frequency of use.
Instrument Primary outcome Secondary outcome Total use Primary use (%) Sensitivity analysis (%)†
Visual Analogue Scale of back pain intensity [22] 119 86 205 29.7 28.2
Roland-Morris Disability Questionnaire [23] 58 94 152 14.5 20.7
Oswestry Disability Index [24] 36 84 120 9.0 10.4
Pain Intensity Numerical Rating Scale [25, 26] 37 39 76 9.2 8.7
Patient Rated Global Assessment (TQ) [27]* 10 53 63 2.5 2.5
PROM = Patient-reported outcome measure
* Example reference only
† Of proportional use as primary outcome measure
doi:10.1371/journal.pone.0164573.t002
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smoother intersects the x-axis at 1982, the year of its publication, it was not recorded as used in
any included trials until 1987. As such, these Lowess lines should be interpreted as a general
impression of trend only. We have included as an additional file (S1 Fig) the plot with a
smoother of half the bandwidth, to depict more sensitive trend-lines.
Reporting methods and analytical approach
For the two most commonly used outcomes, the VAS-P and the RMDQ, reportingmethods
include describingmean changes (within groups) or mean differences (between groups), P-val-
ues for changes or differences, and standard deviations (Table 3). Confidence intervals were
only provided in around 40% of trials. Few authors reported individual improvements. The t
test has been the most common analytical approach, followed by regression analyses. The most
common covariates used in adjusted models were baseline score, sex, age, study centre, and epi-
sode duration, respectively. In 4% of trials utilising the VAS-P or RMDQ, authors present
within-group analyses only.
Discussion
We discuss the results and consider their implications in three sections.We consider these data
and past recommendations for core sets of outcome measures in back pain trials (Respice), the
current situation and emerging recommendations for core sets (Adspice), and implications for
the future of outcome measure use in back pain trials (Prospice).
Fig 3. The five most common back-specific patient reported outcome measures. The figure shows the
use of the five most common back-specific patient reported outcome measures as primary and secondary
outcome measures.
doi:10.1371/journal.pone.0164573.g003
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Respice
The results show that the most commonly used domains in back-specific outcome measures
over the whole time-periodof interest are domains and PROMs that were included in the mil-
lennial recommendations. The millennial recommendations of Deyo et al in 1998, updated by
Bombardier et al in 2000, recommendmeasurement in the domains of pain, function, well-
being, disability, and work disability and both recommended using the VAS-P and NRS for
measuring pain, and the RMDQor ODI for measuring function (disability). [1, 2] TheWorld
Health Organisation made back-specific recommendations to measure pain, disability, and
depression, in 1999, recommending the VAS-P and the ODI be used as primary outcome mea-
sures in trials. [3] International Classifications of functioning (ICF) categories were later pro-
posed, recommending 78 (comprehensive) or 35 (brief)domains of measurement for LBP in
2004. [28] The brief set, intended in particular for use in clinical studies, included body func-
tions, structures, activities and participation and environmental factors. The recommendations
were criticised for having incomplete coverage. [29]
If the millennial recommendations for measurement instruments had impacted practice
then notwithstanding the time it takes for recommendations to be implemented, one might
expect relative increases in proportional use trajectories sometime after the publication of the
recommendations at the turn of the millennium. There is possibly a post-millennial increase in
trajectory in the VAS-P and ODI; there may be a decrease in use of the RMDQ. As these data
represent a population of trials over the time period, inferential statistics are unnecessary, and
the millennial recommendations appear to have had a limited or inconsistent impact on actual
use.
Fig 4. Domains of measurement in non-specific low back pain trials. The figure shows the domains of
measurement in non-specific low back pain trials published between 1980 and 2012.
doi:10.1371/journal.pone.0164573.g004
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Adspice
Towards the end of the 1980–2012 period of interest, researchers suggested outcome measures
are inadequate and that their reassessment needed to be prioritised. [4, 7] A second wave of
recommendations is now emerging. In 2011, Buchbinder et al identified several domains of
measurement not covered by existing core sets, including loss of independence,worry about
the future, and negative or discriminatory actions by others. [30] In 2012, Hush et al recom-
mended adding the Patient Generated Index (PGI) and a global back pain recovery scale to the
core set, specifically to measure recovery. [31] In 2014, Froud et al showed social components
were not adequately represented in measurement. [32] The results in the current study high-
light the absence of measurement in social domains; although social factors are covered to
some extent within the domain of health-related quality of life.
In 2014, a National Institutes of Health (NIH) Task Force recommended using Patient
ReportedOutcomesMeasurement Information System (PROMIS) measures as a minimum
dataset in all NIH-funded LBP research; permitting the RMDQ to substitute the PROMIS
physical activity items if more extensive ‘legacymeasures’ are required. [14] In 2015, Froud
et al extended the Hush recommendation for patient-centric instruments, such as the PGI and
TQ, for trial outcome measurement more generally, after demonstrating that people may not
attend to thinking about their back pain when completing the RMDQ and that changes in
RMDQ score can be independent of changes in back pain. [8, 31] In 2015, Chiarotto et al rec-
ommended three domains for inclusion in a core set, including physical functioning, pain
intensity and health-related quality of life. [33]
Fig 5. The five most common back-specific patient-reported outcome measures: Relative use by year.
The figure shows relative frequency of use for the most common back-specific patient-reported outcome
measures, by publication year.
doi:10.1371/journal.pone.0164573.g005
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Thus, it may currently be difficult from a trialist’s perspective to decide upon appropriate
primary and secondary outcomes in the design-phase of nsLBP trials.We suggest that this
requires careful future attention from groups making core set recommendations, and we dis-
cuss this in the next section. In the meantime, given the widespread use shown in the results,
there may be some value in using either the VAS-P or RMDQ as an outcome measure in
nsLBP trials as this facilitates the greatest cross-comparison. Choices of secondary outcomes
might include some of the more patient-relevant and coverage-improving domains, such as the
PGI and TQ. The results showed that some domains (for example, adverse events and adher-
ence) are only ever measured as secondary outcomes. In our view this is reasonable (unless the
research question relates to adverse events) since the primary focus across most trials and core
set recommendations has emphasis on pain and function.
Table 3. Reporting methods and statistical analysis: Prevalence of use.
Details VAS-P(%) RMDQ(%) Totals(%)
Usage 205 (100) 152 (100) 357 (100)
Reporting method
Mean or mean difference 179 (87) 126 (83) 300 (85)
P-values 162 (79) 109 (72) 271 (76)
Standard deviation 134 (65) 98 (64) 232 (65)
Median 22 (11) 14 (9) 36 (10)
Range or IQR 20 (10) 13 (9) 33 (9)
Standard error 18 (9) 18 (12) 36 (10)
Confidence intervals 62 (30) 76 (50) 138 (39)
Number/proportion improved* 20 (10) 8 (5) 28 (8)
Number needed to treat 2 (1) 5 (3) 7 (2)
Odds ratio (improvement) 3 (1) 9 (6) 12 (3)
Relative risk (improvement) 1 (0) 6 (4) 7 (2)
Percentage change score 25 (12) 15 (10) 40 (11)
Standardised mean difference 9 (4) 11 (7) 20 (6)
Graphs and tables
Table 174 (85) 119 (78) 293 (82)
Line chart 60 (29) 39 (26) 99 (28)
Bar chart 29 (14) 9 (6) 38 (11)
Other 8 (4) 9 (6) 17 (5)
Statistical analysis
ANCOVA regression / mixed model 53 (25) 64 (42) 117 (33)
ANOVA/MANOVA regression / mixed model 74 (36) 39 (26) 113 (32)
t test 93 (45) 43 (28) 136 (38)
Non-parametric test† 68 (33) 37 (24) 105 (29)
Other 18 (9) 9 (6) 27 (8)
Within-group analysis only 11 (5) 3 (2) 14 (4)
Test not described 10 (5) 10 (7) 20 (6)
VAS = Visual analogue scale
RMDQ = Roland-Morris Disability Questionnaire
IQR = Interquartile range
* Where ‘improvement’ is defined by the change in score of a specified magnitude
† e.g. Wilcoxon, Friedman’s, Mann Whitney U, or Kruskal Wallis
doi:10.1371/journal.pone.0164573.t003
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Prospice
There is a risk that overlaps or contractions between and within the millennial and current rec-
ommendations may continue to give a discordant message to trialists. For example, the millen-
nial Deyo/Bombardier recommendations suggested use of VAS-P or NRS (pain) and RMDQ
or ODI (function) whereas theWorld Health Organisation recommended only VAS-P and
ODI for measuring these domains. Currently, researchers are taking slightly different direc-
tions with their recommendations for the future (see above). Future divergences in recommen-
dations may benefit from clear justification and argument. One driving issue may be that
researchers disagree upon fundamental clinical measurement properties of instruments. For
example, although the RMDQ is the secondmost commonly used outcome in nsLBP trials, it
has gained both criticism and support of its clinimetric properties. [8, 27, 34] An underlying
issue here may be disagreement on and heterogeneity in how key clinimetric assessments, such
as test-retest studies and responsiveness studies, are conducted. [35–37] The Consensus-based
Standards for the Selection of Health Measurement Instruments (COSMIN) checklist may go
some way towards helping with this, and it may be that new instruments, with a focus on per-
formance, coverage, and patient-relevance need to be developed prior to future recommenda-
tions beingmade. [38]
The historical data in the current study suggest that the current wave of recommendations
may be set to have limited or inconsistent impact on practice. In future, consideration may
need to be given to mechanisms for maximising impact of recommendations and affecting
change. We suggest that to maximise impact it may be worth considering (1) the consistency of
recommendations, which might be facilitated through (2) inclusivity—a more widespread and
comprehensive collaboration betweenmethodologistsworking on outcome measures, along
with clinimetric/psychometric experts, and domain-specific experts where required, in addi-
tion to clinical experts. One approach to achieving this may be Delphi technique, which is sup-
ported by the Core OutcomeMeasures in Effectiveness Trials (COMET) initiative, with
consideration given to fully reporting panel disagreement and lack of consensus. [39] Finally,
generating sufficient (3) participation or ‘buy-in’ from trialists with acquisition of support, and
a clear and implementable transition strategy to manages the large lag-times from trial concep-
tion to publication, may help to avoid fragmentation in outcome measure use. It may be that
amendments to well-adopted check-lists would also help. The Standard Protocol Items: Rec-
ommendations for Interventional Trials (SPIRIT) check list strongly encourages trialists to
explain the clinical relevance of chosen outcomes in trial protocols (item 12). [40] However,
for trial reporting, the Consolidated Standards of ReportingTrials (CONSORT) statement (in-
particular item 6a), might be modified to encourage authors to discuss any divergences from
recommended core sets or justify outcome measurement selection, which over time, may help
to homogenise outcome measurement across similar trials. [41] Additionally, it may be that
public and private funders, as stakeholders with a vital interest in maximising the use of clinical
trial data, are well-placed to encourage trial teams to carefully consider outcome selection prior
to their awarding a grant for a trial.
Reporting methods and analysis
Specific recommendations for including individual improvements when reporting the out-
comes of back pain trials were not made until 2011. [13] These were reiterated by the NIH task
force in 2014. [14] The 1980 to 2012 data in the current study are not consistent with the rec-
ommendations, but the results of the current study will allow future monitoring of the impact
of these or future recommendations.
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It is encouraging that the majority of authors report between-group differences and a rea-
sonable proportion (33%) report adjusted models. Adjusted models improve the precision of
estimates by taking account of imbalances that exist between groups notwithstanding randomi-
sation. [42] Few authors have used inappropriate analytical methods, such as analysing only
within-group changes; meaning it is not possible to differentiate treatment effect from regres-
sion to the mean.
Comparisons to existing research
Litcher-Kelly et al report, from a systematic review of musculoskeletal clinical trials, that the
most frequently used instruments were the VAS (60%), and the NRS (12%), with an RMDQ
prevalence of 14%. [43] These data are not directly comparable to ours since the study popula-
tion and publication years differ. In 2004, Müller et al identified 84 different back-specific
PROMs and showed that the OswestryDisability Questionnaire and the RMDQwere most
commonly cited. [9] In 2011, Chapman et al also reviewedwhich outcome measures had been
cited in back pain trials between 2006 and 2011. [10] They found that the most cited functional
measure was the ODI and that the most cited pain measure was the NRS. Counting citations
may not reflect actual use. In some cases, citations may not be given and for long-running out-
comemeasures, such as the VAS, references may not be uniform. For example, Huskisson is
commonly credited with developing the VAS, in 1974, but he is not uniformly credited with it.
[22] There is evidence that the VAS was being used at least as far back as 1921. [44] Also, some
citations will reference validatory work.
In other fields, Araújo et al have shown that recommendation of core sets of measurement
in gout have not impacted practice. [45] Page et al showed in 2015 that shoulder pain trials suf-
fer from having no core measurement sets recommended. [46] Relatively the situation in back
pain research may be similar or better, respectively.
Nuovo et al examined the prevalence of reporting of absolute risk reduction (ARR) and
number needed to treat (NNT) in RCTs published in five mainstreammedical journals. [47]
Evaluating publications in 1989, 1992, 1995, and 1998 they found that amongst 359 articles
that ARR was reported in 18 (5.0%) reports, and that NNT was used in eight (2.2%). This is
similar to our study, in which 8% reported the number or proportion of improvements (a cod-
ing in our reviewwhich subsumed ARR), and 2% of trials reportedNNT.
Strengths and limitations
A strength of our research is provision of prevalence data based on actual use, rather than
using citations as a proxy. Other authors have reviewedwhat outcome measures exist for LBP,
but have not estimated prevalence of use. [48–50]
We acknowledge that it is preferable to conduct a systematic review using a singular search
pattern. As the EGLBP search was comprehensive, included all interventions, and we had pre-
viously used it to identify all nsLBP trials, we reasoned it had good cross-coverage with out
later search. Also, we did not search PsycINFO and HTA reports, due to good cross-coverage
from the other databases. This fragmented search strategymay be viewed as a limitation. How-
ever, in comparison to Castellini et al, who reviewed back pain trials published after 1968 and
included 222 trials, we judge our search to have been comprehensive. [51]
We adopted a 20% validation approach rather than full independent reviewer extraction for
all variables. We used full independent abstraction when abstracting details of reportingmeth-
ods and analysis as validation revealed inadequate agreement only on these variables. While
full independent abstraction on all variables would have improved validity, as our focus was
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methodological and not on estimating a treatment effect, we considered the approach to be
reasonable.
Our sensitivity analysis, using only the first two of four criteria for judging a primary out-
comemeasure, showed similar results for estimates of prevalence of use for all but the RMDQ.
Few additional (only eight instances) RMDQprimary outcomes were identified using criteria 3
or 4. It may be that, unlike users of other primary outcome measures, those who use the
RMDQ as a primary are relatively more likely to explicitly declare it as a primary, or perform a
sample size calculation based on detecting a difference in RMDQ score between groups. We
note that the difference between estimating prevalence of use using only the first two criteria,
or all four criteria, does not change the relative ranking of most common usage of primary out-
comemeasures and that, using either method, the RMDQ is the secondmost commonly used
primary outcome measure.
Conclusions
The Visual Analogue Scale of pain intensity and the RolandMorris Disability Questionnaire
have beenmost commonly used in back pain trials. Recommendations for standardising out-
comes may have had a limited or inconsistent effect on practice. Analytical and reporting prac-
tice is encouraging, although there is still room for improvement. Research groups planning to
make further recommendations on core outcome measures for back pain may have more
impact if they consider better ways of generating trialist buy-in.
Supporting Information
S1 Text. Typical search strategy. A typical search strategy used in the systematic review.
(PDF)
S1 Table. Characteristicsof included trials.A table showing the characteristics of included
trials and their references.
(PDF)
S2 Table. Characteristicsof excluded trials.A table showing the characteristics of excluded
trials and their references.
(PDF)
S1 Fig. Most commonly usedmeasures over time, standardisedby the number of annual
publications.The figure shows the most commonly usedmeasures over time, standardised by
the number of annual publications, using a Lowess smoother of half the bandwidth of that
shown in Fig 5, in case more sensitive trend-lines are preferred.
(TIF)
S1 Checklist.PRISMA checklist.A completed PRISMA checklist for the systematic review.
(PDF)
Acknowledgments
Thanks are due to Høyskole Kristiania,Warwick Medical School, Cabrini Institute, and Barts
and the London Charity for funding this work. Three of the authors (SP, RB, and MU) are
employed by one of the funders. RF is employed by two of the funders.
Author Contributions
Conceptualization:RFMU SE RB.
Outcome Measures and Reporting Methods in Low Back Pain Trials: A Systematic Review
PLOS ONE | DOI:10.1371/journal.pone.0164573 October 24, 2016 13 / 16
Data curation:RF PB DR TB.
Formal analysis:RF.
Funding acquisition: RFMU SE RB.
Investigation: RF SP TB PB DR SE RBMU.
Methodology:RFMU SE RB.
Project administration:RF.
Software:RF.
Supervision:RF SE RBMU.
Validation: RF SP TB PB DR SE.
Visualization: RF DRMU.
Writing – original draft:RF.
Writing – review& editing: RF SP TB PB DR SE RBMU.
References
1. Deyo RA, Battie M, Beurskens AJ, Bombardier C, Croft P, Koes B, et al. Outcome measures for low
back pain research. A proposal for standardized use. Spine. 1998; 23(18):2003–13. doi: 10.1097/
00007632-199809150-00018 PMID: 9779535
2. Bombardier C. Outcome assessments in the evaluation of treatment of spinal disorders: Summary and
general recommendations. Spine. 2000; 25(24):3100–3. doi: 10.1097/00007632-200012150-00003
PMID: 11124724
3. Jayson M: Outcome measures for back pain: introduction, justification, and epidemiology. in “Low back
pain initiative” Geneva: World Health Organisation; 1999.
4. Foster NE, Dziedzic KS, van der Windt DA, Fritz JM, Hay EM. Research priorities for non-pharmaco-
logical therapies for common musculoskeletal problems: nationally and internationally agreed recom-
mendations. BMC Musculoskelet Disord. 2009; 10:3. doi: 10.1186/1471-2474-10-3 PMID: 19134184
5. Mullis R, Barber J, Lewis M, Hay E. ICF core sets for low back pain: do they include what matters to
patients? J Rehabil Med. 2007; 39(5):353–357. doi: 10.2340/16501977-0059 PMID: 17549324
6. Hush JM, Refshauge K, Sullivan G, Souza LD, Maher CG, McAuley JH. Recovery: what does this
mean to patients with low back pain? Arthritis Rheum. 2009; 61:124–131. doi: 10.1002/art.24162
PMID: 19116958
7. Hush JM, Refshauge KM, Sullivan G, De Souza L, McAuley JH. Do numerical rating scales and the
Roland-Morris Disability Questionnaire capture changes that are meaningful to patients with persistent
back pain? Clin Rehabil. 2010; 24(7):648–57. doi: 10.1177/0269215510367975 PMID: 20530647
8. Froud R, Ellard D, Patel S, Eldridge S, Underwood M. Primary outcome measure use in back pain trials
may need radical reassessment. BMC Musculoskelet Disord. 2015; 16:88. doi: 10.1186/s12891-015-
0534-1 PMID: 25887581
9. Muller U, Duetz MS, Roeder C, Greenough CG. Condition-specific outcome measures for low back
pain. Part I: Validation. Eur Spine J. 2004; 13(4):301–13. doi: 10.1007/s00586-003-0665-1 PMID:
15029488
10. Chapman JR, Norvell DC, Hermsmeyer JT, Bransford RJ, Devine J, McGirt MJ, et al. Evaluating com-
mon outcomes for measuring treatment success for chronic low back pain. Spine. 2011; 36(21 Suppl):
S54–S68. doi: 10.1097/BRS.0b013e31822ef74d PMID: 21952190
11. Froud R, Underwood M, Carnes D, Eldridge S. Clinicians’ perceptions of reporting methods for back
pain trials: a qualitative study. Br J Gen Pract. 2012; 62(596):e151–e159. doi: 10.3399/
bjgp12X630034 PMID: 22429424
12. McGettigan P, Dianne S, O’Connell K, Hill S, Henry D. The Effects of Information Framing on the Prac-
tices of Physicians J Gen Intern Med. 1999; 14(10): 633–642. doi: 10.1046/j.1525-1497.1999.09038.x
PMID: 10571710
Outcome Measures and Reporting Methods in Low Back Pain Trials: A Systematic Review
PLOS ONE | DOI:10.1371/journal.pone.0164573 October 24, 2016 14 / 16
13. Froud R, Eldridge S, Kovacs F, Breen A, Bolton J, Dunn K, et al. Reporting outcomes of back pain tri-
als: A modified Delphi study. Eur J Pain. 2011; 15(10):1068–74. doi: 10.1016/j.ejpain.2011.04.015
PMID: 21596600
14. Deyo RA, Dworkin SF, Amtmann D, Andersson G, Borenstein D, Carragee E, et al. Report of the NIH
Task Force on research standards for chronic low back pain. Spine J. 2014; 14(8):1375–1391. doi: 10.
1016/j.spinee.2014.05.002 PMID: 24950669
15. COST B13. European guidelines for the management of low back pain. Eur Spine J. 2006; 15(S2).
16. Eldridge S. Assessing, understanding, and improving the efficiency of cluster randomised trials in pri-
mary care. PhD thesis. Queen Mary University of London; 2005.
17. Eldridge S, Ashby D, Bennett C, Wakelin M, Feder G. Internal and external validity of cluster rando-
mised trials: systematic review of recent trials. BMJ. 2008; 336(7649):876–80. doi: 10.1136/bmj.
39517.495764.25 PMID: 18364360
18. Diaz-Ordaz K, Froud R, Sheehan B, Eldridge S. A systematic review of cluster randomised trials in res-
idential facilities for older people suggests how to improve quality. BMC Med Res Methodol. 2013;
127:13. doi: 10.1186/1471-2288-13-127 PMID: 24148859
19. Froud R, Bjørkli T, Bright P, Rajendran D, Buchbinder R, Underwood M, et al. The effect of journal
impact factor, reporting conflicts, and reporting funding sources, on standardized effect sizes in back
pain trials: a systematic review and meta-regression. BMC Musculoskeletal Disorders. 2015; 16:370.
doi: 10.1186/s12891-015-0825-6 PMID: 26620449
20. Froud R. Improving interpretation of patient-reported outcomes in low back pain trials. PhD thesis.
Queen Mary University of London; 2010.
21. Eldridge SM, Ashby D, Feder GS, Rudnicka AR, Ukoumunne OC. Lessons for cluster randomized tri-
als in the twenty-first century: A systematic review of trials in primary care. Clin Trials. 2004; 1:80–90.
doi: 10.1191/1740774504cn006rr PMID: 16281464
22. Huskisson E. Measurement of Pain. The Lancet. 1974; (ii: ):1127. doi: 10.1016/S0140-6736(74)
90884-8
23. Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and
sensitive measure of disability in low-back pain. Spine. 1983; 8(2):141–4. doi: 10.1097/00007632-
198303000-00004 PMID: 6222486
24. Fairbank JC, Couper J, Davies JB, O’Brien JP. The Oswestry low back pain disability questionnaire.
Physiotherapy. 1980; 66(8):271–3. PMID: 6450426
25. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating
scales. Ann Rheum Dis. 1978; 37(4):378–81. doi: 10.1136/ard.37.4.378 PMID: 686873
26. Childs J, Piva S, Fritz J. Responsiveness of the Numeric Pain Rating Scale in Patients with Low Back
Pain. Spine. 2005; 30(11). doi: 10.1097/01.brs.0000164099.92112.29 PMID: 15928561
27. Beurskens A, de Vet H, Koke A. Responsiveness of functional status in low back pain: A comparison
of different instruments. Pain. 1996; 65:71–76. doi: 10.1016/0304-3959(95)00149-2 PMID: 8826492
28. Cieza L, Stucki G, Weigl M, Disler P, Jackel W, van der Linden S, et al. ICF core sets for low back pain.
J Rehabil Med. 2004; Suppl. 44: :69–74. doi: 10.1080/16501960410016037 PMID: 15370751
29. Mullis R, Barber J, Lewis M, Hay E. ICF core sets for low back pain: do they include what matters to
patients? J Rehabil Med. 2007; 39(5): 353–357. doi: 10.2340/16501977-0059 PMID: 17549324
30. Buchbinder R, Batterham R, Elsworth G, Dionne C, Irvin E, Osborne R. A validity-driven approach to
the understanding of the personal and societal burden of low back pain: development of a conceptual
and measurement model. Arthritis Research & Therapy. 2011; 13(5):R152. doi: 10.1186/ar3468
PMID: 21933393
31. Hush JM, Kamper SJ, Stanton TR, Ostelo R, Refshauge KM. Standardized measurement of recovery
from nonspecific back pain. Arch Phys Med Rehabil. 2012; 93(5):849–855. doi: 10.1016/j.apmr.2011.
11.035 PMID: 22444028
32. Froud R, Patterson S, Eldridge S, Seale C, Pincus T, Rajendran D, et al. A systematic review and
meta-synthesis of the impact of low back pain on people’s lives. BMC Musculoskelet Disord. 2014;
15:50. doi: 10.1186/1471-2474-15-50 PMID: 24559519
33. Chiarotto A, Deyo RA, Terwee CB, Boers M, Buchbinder R, Corbin TP, et al. Core outcome domains
for clinical trials in non-specific low back pain. Eur Spine J. 2015; 24(6):1127–1142. doi: 10.1007/
s00586-015-3892-3 PMID: 25841358
34. Chiarotto A, Maxwell L, Terwee C, Wells G, Tugwell P, Ostelo R. Roland-Morris Disability Question-
naire and Oswestry Disability Index: Which Has Better Measurement Properties for Measuring Physi-
cal Functioning in Nonspecific Low Back Pain? Systematic Review and Meta-Analysis. Physical
Therapy. 2016 doi: 10.2522/ptj.20150420 PMID: 27081203
Outcome Measures and Reporting Methods in Low Back Pain Trials: A Systematic Review
PLOS ONE | DOI:10.1371/journal.pone.0164573 October 24, 2016 15 / 16
35. Froud R, Abel G. Using ROC Curves to Choose Minimally Important Change Thresholds when Sensi-
tivity and Specificity Are Valued Equally: The Forgotten Lesson of Pythagoras. Theoretical Consider-
ations and an Example Application of Change in Health Status. PLoS One. 2014; 9(12):e114468. doi:
10.1371/journal.pone.0114468 PMID: 25474472
36. de Vet HC, Terwee C, Knol DL, Bouter L. When to use agreement versus reliability measures. Clin Epi-
demiol. 2006; 59:1033–1039. doi: 10.1016/j.jclinepi.2005.10.015
37. Froud, R. How we currently measure back pain in O’Dowd FRCS Orth, J. and Hlavsova MSc, MCSP,
HPC, A. (eds). Back Pain Management: Physical and Psychological Treatments, The Biomedical & Life
Sciences Collection, Henry Stewart Talks Ltd, London (online at http://hstalks.com/?t=BL1984087).
38. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN checklist for
assessing the methodological quality of studies on measurement properties of health status measure-
ment instruments: an international Delphi study. Quality of Life Research. 2010; 19:539–549. doi: 10.
1007/s11136-010-9606-8 PMID: 20169472
39. Williamson P, Gargon L, Clarke M, Blazeby J, Altman D. Standards for COS development. COMET
Management Group. 2013; http://www.comet-initiative.org/assets/downloads/Standards.pdf.
40. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleza-Jerić K, et al. SPIRIT 2013 state-
ment: defining standard protocol items for clinical trials. Ann Intern Med. 2013; 158: 200–207. doi: 10.
7326/0003-4819-158-3-201302050-00583 PMID: 23295957
41. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: Updated Guidelines
for Reporting Parallel Group Randomised Trials. PLoS Med. 2010; 7(3): e1000251. doi: 10.1371/
journal.pmed.1000251 PMID: 20352064
42. International Conference on Harmonisation Expert Working Group. Statistical principles for clinical tri-
als E9. ICH tripartite guideline. 1998.
43. Litcher-Kelly L, Martino S, Broderick J, Stone A: A Systematic Review of Measures Used to Assess
Chronic Musculoskeletal Pain in Clinical and Randomized Controlled Clinical Trials. The Journal of
Pain. 2007; 8(12):906–913. doi: 10.1016/j.jpain.2007.06.009 PMID: 17690014
44. Hayes M, Patterson D. Experimental development of the graphic rating method. Psychol Bull. 1921;
18(98).
45. Arau´jo F, Cordeiro I, Ramiro S, Falzon L, Branco J, Buchbinder R. Outcomes assessed in trials of gout
and accordance with OMERACT-proposed domains: a systematic literature review. Rheumatology.
2015; 54(6):981–93. doi: 10.1093/rheumatology/keu424 PMID: 25398382
46. Page MJ, McKenzie JE, Green SE, Beaton DE, Jain NB, Lenza M, et al. Core domain and outcome
measurement sets for shoulder pain trials are needed: systematic review of physical therapy trials. J
Clin Epidemiol. 2015; 68(11):1270–81. doi: 10.1016/j.jclinepi.2015.06.006 PMID: 26092288
47. Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in ran-
domized controlled trials. Jama-Journal of the American Medical Association. 2002; 287(21):2813–
2814. doi: 10.1001/jama.287.21.2813
48. Grotle M, Brox J, Vollestad N. Functional Status and Disability Questionnaires: What Do They
Assess?: A Systematic Review of Back-Specific Outcome Questionnaires. Spine. 2004; 30:130–140.
doi: 10.1097/01.brs.0000149184.16509.73 PMID: 15626993
49. Costa L, Meyer C, Latimer J. Self-report outcome measures for low back pain. Spine. 2007; 32(9). doi:
10.1097/01.brs.0000261024.27926.0f
50. Kopec J. Measuring functional outcomes in persons with back pain. A review of back-specific question-
naires. Spine. 2000; 25(24):3110–3114. doi: 10.1097/00007632-200012150-00005 PMID: 11124726
51. Castellini G, Gianola S, Bonovas S, Moja L. Improving Power and Sample Size Calculation in Rehabili-
tation Trial Reports: A Methodological Assessment. Arch Phys Med Rehabil. 2016; 97(7):1195–201.
doi: 10.1016/j.apmr.2016.02.013 PMID: 26971671
Outcome Measures and Reporting Methods in Low Back Pain Trials: A Systematic Review
PLOS ONE | DOI:10.1371/journal.pone.0164573 October 24, 2016 16 / 16
